ChemoCentryx Initiates Phase II Clinical Trial for CCX168, a Novel Small ... - MarketWatch (press release) PDF Print
MarketWatch (press release)
This randomized, double-blind, placebo-controlled trial will evaluate the safety and tolerability of CCX168 in patients with ANCA-associated renal vasculitis while assessing the potential for reducing or eliminating the use of corticosteroids in these

...

 
Share |
Copyright © 2025 Global Dialysis. All Rights Reserved.